Infervision announced that it received FDA 501(k) clearance for its InferRead Lung CT.AI system which uses AI to automatically perform lung segmentation.
InferRead Lung CT.AI is designed to use AI and deep learning technology to support concurrent reading and aid radiologists in pulmonary nodule detection during the review of chest CT scans, increasing accuracy and efficiency, according to a news release.
The company, which has its U.S. operations based in Philadelphia, said that its lung segmentation system is used at over 380 hospitals and imaging centers around the world, as it also has CE Mark approval in Europe. Infervision believes the system may also help in lung cancer screening programs, helping to detect small nodules.
“We’re excited to be able to make our InferRead Lung CT.AI solution available to the North American market,” Infervision North America director Matt Deng said in the release. “Our clients tell us it has great potential to help provide improved outcomes for providers and patients alike.
“This is our first FDA clearance for the deep-learning-based chest CT algorithm and it will lead the way to better integration of advanced A.I. solutions to help the healthcare clinical workflow in the region. This marks a great start in the North American market, and we are expecting more high-performance AI tools in the near future.”